As the largest integrated healthcare provider in the U.S., the VA presents tremendous opportunity for life sciences companies. This article provides actionable information about the VA's drug benefit design, drug pricing, clinical guidance, and formulary placement and management.
- When Consumer Protection, Unfair Trade Practices, And AI Collide
- Companies To Watch: Athira Pharma
- USPTO Proposed 'Terminal Disclaimer' Rule Could Impact Life Science Patent Protections
- Reading The Room In Oncology Drug Development
- Correct But Misleading: AI Hallucinations In Complex Decision-Making
- Patient Access Challenges Are Changing Pharma Investment Strategies
- Could GenAI Dramatically Reduce The Cost Of Regulatory Medical Writing?
- Cash Needed For Phase 3 Celiac Drug Development
COMPANIES TO WATCH
-
Companies To Watch: Athira Pharma
Athira Pharma is developing small molecule therapeutics for neurodegenerative diseases, including its lead candidate, fosgonimeton, for Alzheimer's disease.
-
Volastra Therapeutics is a drug discovery and development leader in the emerging field of chromosomal instability, a phenomenon that can determine how certain solid tumor cancer cells replicate and grow.
-
OSE Immunotherapeutics is poised to begin a confirmatory and pivotal Phase 3 trial for a novel cancer vaccine targeting the second line in NSCLC, an area of acute unmet need.
-
Antiva Biosciences is exploring a local and global opportunity with a topically administered HPV treatment.
WHERE ARE THEY NOW
-
Where Are They Now? Otsuka
Otsuka Precision Health, a new subsidiary focused on digital therapeutics and other tech-enabled solutions for patients, is a continuation of the company's broader mission described by an Otsuka executive in the pages of Life Science Leader eight years ago.
-
Where Are They Now? SQZ Biotech
SQZ Biotech, a novel cell therapy company with Big Pharma backing, is no more. However, the company's science, and its founding CEO, will continue on under new auspices.
-
Where Are They Now? Novo Nordisk
In a few short years, Novo Nordisk has gone from belt-tightening to parachute pants, and is now replaying a GLP-1 competition with Eli Lilly that kicked off with Victoza and Trulicity ten years ago.
NEWSLETTER ARCHIVE
![ben-main ben-main](https://vertassets.blob.core.windows.net/image/6e9277d5/6e9277d5-6baa-47ef-b2fc-e7eb7e8dfa9c/ben_main.jpg)
- Reading The Room In Oncology Drug Development
- Ten Years In, Project Data Sphere Is Snowballing
- Drug Discovery And Development, Powered By Physician Intelligence
- Why Fusion Pharma Is The Latest Billion Dollar Big Pharma Buy In Radiopharmaceuticals
- A Proactive Approach To 'Unscrupulous’ Patent Practices